1. Home
  2. KLXE vs MAIA Comparison

KLXE vs MAIA Comparison

Compare KLXE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLX Energy Services Holdings Inc.

KLXE

KLX Energy Services Holdings Inc.

N/A

Current Price

$3.24

Market Cap

45.6M

Sector

Energy

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.49

Market Cap

77.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KLXE
MAIA
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.6M
77.1M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
KLXE
MAIA
Price
$3.24
$1.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
307.4K
743.3K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$636,600,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$0.87
52 Week High
$4.50
$3.19

Technical Indicators

Market Signals
Indicator
KLXE
MAIA
Relative Strength Index (RSI) 49.97 62.00
Support Level $3.10 $1.44
Resistance Level $3.45 $1.74
Average True Range (ATR) 0.30 0.09
MACD -0.06 0.02
Stochastic Oscillator 33.67 77.94

Price Performance

Historical Comparison
KLXE
MAIA

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: